

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 June 2002 (20.06.2002)

PCT

(10) International Publication Number
WO 02/47703 A2

- (51) International Patent Classification⁷: A61K 35/78, A61P 37/04
- (21) International Application Number: PCT/NL01/00896
- (22) International Filing Date:
10 December 2001 (10.12.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
09/734,389 11 December 2000 (11.12.2000) US
- (61) Related by addition to earlier applications or grants:
CU Not furnished (ICA)
Filed on Not furnished
KP Not furnished (ICA)
Filed on Not furnished
- (71) Applicant (*for all designated States except US*): NUTRICIA N.V. [NL/NL]; Eerste Stationsstraat 186, NL-2712 HM Zoetermeer (NL).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): GRAUS, Yvo, Maria, Franciscus [NL/NL]; Pienemanstraat 112, NL-6717 WG Ede (NL). SMIT, Hobbe, Friso [NL/NL]; Texel 7, NL-3524 AS Utrecht (NL). OSTERHAUS, Albertus, Dominicus, Marcellinus, Erasmus [NL/NL]; Dr. Breveestraat 16, NL-3981 CH Bunnik (NL). HAGEMAN, Robert, Johan, Joseph [NL/NL]; Weidezoo 52, NL-2742 EV Waddinxveen (NL).
- (74) Agent: PRINS, A., W.; c/o Vereenigde, Nieuwe Parklaan 97, NL-2587 BN The Hague (NL).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU (inventor's certificate), CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EC, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH (utility certificate), GM, HR (consensual patent), HU, ID, IL, IN, IS, JP, KE, KG, KP (inventor's certificate), KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TN, TR, TT (utility certificate), TZ, UA, UG (utility certificate), US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: IMMUNE SYSTEM STIMULATION

(57) Abstract: The present invention relates to a preparation for stimulating or enhancing an immune system comprising one or more agents that stimulate T-lymphocytes *vivo*. Such a preparation can be used in the prophylaxis and/or treatment of a medical condition. The invention further relates to a preparation for use in a pharmaceutical or food product and to a preparation for medical use.

WO 02/47703 A2

Title: Immune system stimulation.

The invention relates to a preparation for stimulating the immune system. The invention further relates to a method of treating and/or preventing a medical condition by administration of said preparation to a human or an animal and to a method to manufacture a product for use in prophylaxis and/or treatment of a medical condition.

The immune system in animals, including humans, plays an important role in prevention and treatment of many disorders/diseases, such as infections by foreign bodies such as bacteria, viruses, parasites, toxins or proteins, but also in the prevention and treatment of various forms of cancer. Viruses or bacteria may for example cause infections in the respiratory tract, or cause systemic infections (e.g. herpes virus). Infections may also be associated with other diseases such as an infection by a *cytomegalo-virus* (CMV) in an AIDS patient or an infection by *pneumococcal sp* in a cancer patient. Such an infection is also referred to as a secondary infection.

In clinical practice, large groups of hospital patients or other persons suffering from an underdeveloped (e.g. neonates) or compromised (e.g. cancer or transplantation patients treated with chemotherapeutics, or part of the elderly population) immune function, suffer at one point in time from (primary or secondary) infections, which may increase the period of hospital stay or the duration of an illness in general. An underdeveloped or compromised immune function of patients may require aggressive treatment with antibiotics, which even can lead to life-threatening situations.

In daily life, also "healthy" persons are frequently infected by a foreign entity such as a virus and/or a bacterium, leading to symptoms such as bad wound healing, pain, fever or general malaise. Commonly known examples thereof are various infections of the respiratory tract, including the throat, and such infections frequently occur in particular after stress (e.g. due to bad weather, heavy exercise or emotional stress).

The functioning of the immune system is *inter alia* related to various chemical substances that are produced *in vivo* or obtained by nutrition.

Administration of such substances in order to support the immune function can help prevention and/or treatment of many diseases. In addition various

5 substances such as antioxidants are known to play a beneficial role in the prevention and treatment of diseases. Antioxidants may prevent damage of healthy cells by radicals, formed by the immune system, that are directed against infecting moieties (infectants).

The presence of chlorogenic acid in an antioxidant composition is
10 reported in United States Patent 5,788,971. In this publication, sunflower seed extract containing chlorogenic acid and green tea leaf extract containing EGCG is said to be able to scavenge free radicals, which may be useful in the treatment of inflammatory disorders.

European patent application 0/906/761 also mentions chlorogenic as
15 a possible antioxidant.

In JP 60243016 an anti-influenza tablet is described containing 3,5-dicaffeoylquinic acid obtained by subjecting a methanol extract of a *Helianthus annuus* seed to counter-current distribution.

In WO 99/34812 a composition comprising baicalin, chlorogenic acid
20 and forsythiaside is reported to have antiviral, antibacterial or immunomodulating properties. According to this publication said composition is capable of increasing the natural killer cell (NK cell) activity and the interferon- α production of peripheral blood cell lymphocytes *in vitro*. It remains unclear from this publication what the contribution of chlorogenic
25 acid is in a composition mentioned in this publication.


With respect to prevention of diseases, there is a limited value to administering substances which may give protection to the subject in a general way. It is however also possible to stimulate the immune system more specifically, such as by vaccination of an animal and human to give protection
30 against a particular disease. Vaccination aims to present an innocuous yet

antigenic form of an infectious organism or its toxin(s), for establishing protective immunity. So called T-lymphocytes play an important role in this process. By vaccination the immune system can very specifically be stimulated to become active against a particular antigen. Large vaccination programs, are
 5 currently applied, both to animals and to humans, against a wide variety of diseases. This vaccination may cause discomfort to a subject that is vaccinated, and sometimes has limited success.

The present invention seeks to provide a preparation to stimulate or to enhance the immune system of animals or humans to be more effective.
 10 Surprisingly it has been found that a preparation comprising one or more agents that stimulate T-lymphocytes proliferation *in vivo* have the desired effect.

Accordingly the invention relates to a preparation for stimulating or enhancing an immune system comprising one or more agents that stimulate T-
 15 lymphocytes *in vivo*.


Highly suitable agents that stimulate T-lymphocytes *in vivo* have been found to be chlorogenic acid (1-caffeoylquinic acid) or a functional analog thereof. Preferred examples of chlorogenic acid and functional analogs thereof may be represented by formula 1:



(Formula 1)

20 wherein "a" represents either a single bond or a double bond and R₁ is only present in case "a" represents a single bond, and wherein at least one of the functional groups R₁-R₄, preferably at least R₄, represents a functional group represented by formula 2 (further referred to as subst. II)

4



(Formula 2)

and the remaining of said functional groups R₁-R₄ are independently chosen from the group formed by -OH, and other substituents -like caffeic acid moiety analogs - that are abundant in a material of a vegetable nature and can be
 5 split off by the intestinal flora. It is to be noted that the compound of formula 1 has the 1 α , 3 α , 4 α , 5 β -hydroxy configuration.

Preferred functional analogs of chlorogenic acid in a preparation according to the invention are 4-caffeoylquinic acid, neochlorogenic acid (3-caffeoylquinic acid), dicaffeoyl quinic acids wherein the 1 and 5 positions are
 10 substituted (1,5-dicaffeoylquinic acid), isochlorogenic acids (*i.e.* dicaffeoyl quinic acids substituted on 3 and 4 positions, 3 and 5 positions or 3, 4 and 5 position (3,4,5 tricafeoyl quinic acid)), kryptochlorogenic acid (4-O-caffeoylquinic acid, cynarin (1,3-O-caffeoylquinic acid), 1,3,4,5-O-tetracaffeoylquinic acid and caffeoylshikimic acids, in particular 5-O-
 15 caffeoylshikimic acid. With reference to formula 1, these analogs have the following chemical structures:

Compound	R ₁	R ₂	R ₃	R ₄
(-)-quinic acid	OH	OH	OH	OH
1-O-caffeoyl quinic acid	subst. II	OH	OH	OH
chlorogenic acid (5-O-caffeoylquinic acid	OH	OH	OH	subst. II
kryptochlorogenic acid	OH	OH	subst. II	OH
neochlorogenic acid	OH	subst. II	OH	OH
cynarin (1,3-O-dicaffeoylquinic acid)	subst. II	subst. II	OH	OH
1,5-O-dicaffeoylquinic acid	subst. II	OH	OH	subst. II
3,4-O-dicaffeoylquinic acid	OH	subst. II	OH	OH
3,5-O-dicaffeoylquinic acid	OH	subst. II	OH	subst. II
4,5-O-dicaffeoylquinic acid	OH	OH	subst. II	subst. II
1,2,3,4-O-tetracaffeoylquinic acid	subst. II	subst. II	subst. II	subst. II

Chlorogenic acid and functional analogs thereof will be referred to herein as *CA-compounds*.

A CA-compound in a preparation according to the invention may be of synthetic origin, or of natural origin. Chlorogenic acid and derivatives thereof can be synthesized by applying one of the methods known in the art, such as the method described by Panizzi *et al.* (Gazz.Chim.Ital, 86, 913, (1956)). Alternative sources for chlorogenic acid and its derivatives are *inter alia* *Vaccinium myrtillus* extracts, potato extracts (pressing juice) and sunflower extracts.

10 The preparation may comprise plant material in raw form. This may be advantageous, in particular to lower the cost-price of a preparation. A CA-compound in the preparation is preferably of natural origin, e.g. as an extract of one or more plants. The extracts (or raw material) can for example be taken from plants like *Echinacea sp.*, *Panax Ginseng*, green coffee bean, green cacao
15 been, hawthorn, green tea, elder tree, artichoke (*Cynara scolymus*), guerana, butterbur. Phoenix spp, *Butia capitata*, Dandelion, various members of the dicotylus plants, in particular members of the *Compositae*, as well as *Arnica montana* and Birch tree or combinations thereof. Several suitable extraction methods are known in the art. A highly preferred extraction method typically
20 comprises crushing of the plant material, blending the crushed material with a polar, preferably aqueous, solvent, filtering the slurry of crushed material and polar solvent and purifying the filtrate. Several purification methods like one-step or multi-step liquid-liquid extraction, solid phase extraction, chromatography and the like are known from the state of the art. A possible
25 extraction method is disclosed in WO 99/34812.

The T-lymphocyte stimulating properties of CA-compounds may give an important boost to the activity of the immune systems. The term "T-lymphocytes" is commonly used to describe a family of leucocytes originating from lymphoid progenitors that have differentiated in the thymus and
30 descended cells thereof. Cytotoxic lymphocytes may develop from precursors

which are activated by antigen plus major histocompatibility complex class I (MHC class I) and are expanded and mature by the action of interleukin-2 and ill-defined maturation factors produced by helper T-lymphocytes. [ref. Ivan Roitt, Essential Immunology, 7th Ed., (1991) Blackwell Scientific Publications, Oxford, UK]. T-lymphocytes have several crucial functions in the immune system. They are responsible for the recognition of an entity which is foreign to the body (an antigen) and they are involved in the development of a specific immune response in order to eliminate an antigen. Such an antigen may be a pathogen originating from outside the body, like a bacterium, a virus or parasite, but it may also be a neoplastic somatic cell that has obtained a neo-antigenic structure. A protein or peptide structure such as a prion, a vaccine or a toxin as well as other non-cell structures can also be antigenic. Once an antigen has entered the body, it is taken up, processed and presented by so called antigen presenting cells, *i.e.* dendritic cells, to precursor T-lymphocytes. Subsequently, those T-lymphocytes that recognize the antigen need to proliferate in order to mount a significant immune response. Activated (helper) T-lymphocytes are required to support the formation of specific antibodies by B-lymphocytes, which predominantly clear foreign entities from the body.

In addition the helper T-lymphocytes (T-helper cells) support the formation of cytotoxic T-lymphocytes, which are *inter alia* able to eliminate virus-infected cells or neoplastic cells which are developed in several forms of cancer. Cytotoxic T-lymphocytes may also play a role in the defense against a parasite and they are able to release interferon-gamma. Interferon-gamma may contribute to making cells surrounding an infected cell resistant to viral spread.

In order to be effective it is crucial that the specific T-helper cells are abundant in sufficient numbers or proliferate to reach sufficient numbers, as soon as possible after the appearance or arising of an antigen in the body. It has been found that a preparation according to the invention can be used to increase the proliferation of antigen-specific T-lymphocytes, such as T-helper

cells and cytotoxic T-lymphocytes. A preparation may also promote differentiation of cells to become functional T-lymphocytes.

A preparation according to the present invention may also stimulate T-helper cells to develop particular cytokines which support other types of lymphocytes. Examples of such lymphocyte supporting cytokines are
5 interleukin-2 (IL-2), interleukin-6 (IL-6) and interferon-gamma (IFN- γ).

The general nature of the immune stimulating properties of preparations according to the invention enables its employment in a broad field of applications. The person skilled in the art will recognize that the type of
10 foreign entity is not essential. Some examples of viruses against which a preparation according to the invention stimulates the immune system are DNA viruses, like *Pox-viridae*, *Herpes-viridae* (e.g. *herpes*, *simplex*, *varicella* *zoster* virus, CMV), *Adenoviridae*, *Papavoviridae*, *Hepadnaviridae*, *Parvoviridae*, RNA viruses like *Reo-viridae*, *Picornaviridae* (e.g. *Polio-virus*,
15 *Echo-virus*, *Entero-virus*, *Rhino-virus*), *Toga-viridae*, *Flavi-viridae*, *Coronaviridae*, *Rhabdo-viridae*, *Paramyxo-viridae* (e.g. *parainfluenza*, Mumps, measles and RS virus), *Orthomixo-viridae*, *Filo-viridae*, *Bunya-viridae*, *Arenaviridae*, *Calici-viridae*, and *Retroviridae*. According to the invention also *Papilloma*, *influenza*, HIV, HTLV, *Corona* and Epstein Barr can be prevented
20 or treated.

Bacterial infections that can be prevented or treated by using a preparation according to the invention include those that can occur as a secondary infection after a virus infection (for example after a common cold) or during another disease. The preparation can be used to stimulate lymphocytes
25 against all kinds of bacteria. Some examples are *pneumococcus* sp, *Staphylococcus aureus* and bacteria that enter the blood circulation e.g. in situations of gut leakage, sepsis and the like.

Some examples of parasites against which the invention can be directed are protozoan and metazoan parasites, including but not limited to

Leishmania donovani, *Trypanosoma cruzi*, *Toxoplasma gondii*, *Plasmodium* sp., *Theilaria parva* and *Schistosomas* sp..

As already indicated, a preparation according to the invention stimulates or induces T-lymphocytes in a general way. It has been found that the preparation is particularly suitable for use before, during and after situations in which the immune system is highly challenged in order to increase the resistance of a patient or a "healthy" person. Such situations may be surgery, heavy physical exercise, exposure to bad weather conditions, sore throat, coughing, fever, general malaise and the like.

10 The present preparation is however not only effective in the prophylaxis and/or treatment of infection by one or more antigens, but the immune system may also be stimulated to deal with a neoplastic cell which may develop in several forms of cancer. Thus the invention can help to decrease tumor growth, optionally in combination with prevention or
15 treatment of occasional infections that may occur during or after cancer therapy, such as radiation- or chemotherapy. Accordingly the invention relates to a preparation for stimulating T-lymphocytes for use in treatment and/or prophylaxis of cancer, infection by a parasite, a toxin, a virus, and/or a bacterium, to a method for stimulating T-lymphocytes by administration of
20 said preparation and to a method which is part of a prophylactic or treatment protocol for cancer. Such a protocol includes, but is not limited to, a vaccination protocol with autologous tumor cells, tumor antigen autologous dendritic cells or other immunotherapeutic protocols used in the treatment of different cancers. In addition to a general stimulation of T-lymphocytes, it has
25 surprisingly been found that in an embodiment of the invention, further comprising an innocuous yet antigenic form of an infectious organism and/or a toxin thereof, chlorogenic acid and/or a functional analog thereof may also act as an adjuvant, i.e. chlorogenic acid and/or a functional analog thereof may stimulate the specific immune response, directed by T-lymphocytes, against
30 said infectious organism and/or said toxin. Besides a more general effect that a

CA-compound may have on the immune system, as an adjuvant, a CA-compound may enable an antigen to be presented more effectively to a T-lymphocyte, or even to be transported into a T-lymphocyte and possibly to activate that particular T-lymphocyte. Thus the CA-compound may enable or
5 enhance the induction of an immune response against the particular pathogenic antigen, against which the vaccine is directed. Thus T-lymphocyte stimulation by a CA-compound allows the use of a preparation according the present invention to be used in a vaccine. Accordingly, an embodiment of the invention is a vaccine comprising chlorogenic acid and/or a functional analog
10 thereof as adjuvant.

The use of a chlorogenic acid or a functional analog thereof as adjuvant is another embodiment of the invention. It may be used in a vaccine for immunization of a subject or a population. The vaccine may further comprise one or more additives, such as those that will be discussed below. The
15 method of vaccination may be orally or subcutaneously or by another method known in the art. In a preferred embodiment the vaccine is administered orally.

For various reasons, a preparation according to the invention may comprise a one or more other active substances or additives. It has been found
20 that a stimulation of T-lymphocytes can further be enhanced if a preparation according to the invention further comprises a particular type of cytokine or an agent that is capable of inducing such type of cytokine. The presence of such a compound may lead to a quicker and/or larger immune response, which may be particularly desirable when fast recovery of a patient is wanted *e.g.* due to his
25 bad condition, or for economical reasons. A larger response is also useful in case one aims to prevent the use of antibiotics, *e.g.* because development of tolerance of a micro-organism against an antibiotic is feared.

The additional effect of a cytokine inducing agent in combination with a CA-compound also allows inclusion of lower amounts of said CA-
30 compound in a preparation without decrease in effectiveness. This reduction

can lead to a reduced cost-price and improved organoleptic properties of preparations according to the invention.

Interferon-gamma is a preferred cytokine in relation to this invention and accordingly a cytokine inducing agent in a preparation should preferably be capable of inducing the production of interferon-gamma. It is to be noted that preparations intended for oral administration will generally not contain interferon-gamma itself, but rather an agent capable of inducing the production of interferon-gamma, as it may be digested in the gastro-intestinal tract. In preparations for other types of administration, such as vaccines, interferon-gamma itself may be used. Preferred examples of interferon-gamma inducing agents are specific polysaccharides, zinc salts and N-acetyl cysteine. Suitable zinc sources can for example be any edible food-grade zinc salt, such as an inorganic salt like zinc carbonate, zinc sulfate, zinc oxide, zinc chloride etc. Examples of suitable polysaccharides are arabinogalactans from *Baptisia tinctoria*, *Echinacea* species, *Larix occidentalis*, *Angelica acutiloba* or other polysaccharides that can be isolated from *Echinacea* species, *Thuja occidentalis* and *Panax ginseng*. Polysaccharides from fungi, in particular from *Flammulina velupites* may also be used.

Polysaccharides that can enhance the cellular immune response are thought to induce interferon production as well, e.g. polysaccharides from *Arnica montana* cell cultures (stimulating TNF α release in macrophages), *Plantago spp* (increasing NK cell activity), *Achyrocline satureioides*, *Aconitum officinalis*, *Angelica acutiloba*, *Aristolochia officinalis*, *Astragalus gummerifa*, *A. membranaceus*, *A. mongholicus*, *Avena sativa*, *Bambusa vulgaris*, *Baptisia tinctoria*, *Bryonia dioica*, *Calendula officinalis*, *Carthamus tinctorius*, *Chamomilla recutita*, *Echinacea angustifolia*, *E. pallida*, *E. purpurea*, *Eleutherococcus senticosus*, *Eupatorium cannabinum*, *Silene vulgaris*, *Thuja occidentalis*, *Triticum sativum*, *Vincetoxicum officinalis*, *Viscum album*.

Naturally a preparation according to the invention may also comprise several cytokine inducing agents, including the ones mentioned above.

5 A preparation according to the invention for use in the treatment of cancer may also comprise one or more compounds with an anti-tumor activity. Examples of such compounds include polysaccharides which demonstrate anti-tumor activity *in vivo*. These are thought to act via a similar pathway as the polysaccharides stimulating interferon production such as mentioned above. In general they also have an immunostimulating activity. Examples are
10 polysaccharides (in particular β -1,3-glucans and/or β -1,4-glucans) from the mushrooms, *Lentinus edodes* (lentinan), *Schizophyllum commune* (schizophyllan), *Phytophthora parasytica*, *Grifola frondosa*, *Sclerotinia clerotiorum*, *Ganoderma lucidum*, *Coriolus versicolor* (krestin) and the like, or from the plants *Morinda citrifolia* fruit or *Viscum album* and the like.

15 The anti-carcinogenic effect of β -1,3-glucans is shown in US 4,454,286, for example for β -1,3-glucans from *Schizophyllum commune*, *Auricularia spp* and lentinan from *Lentinus edodes*. Methods for isolating polysaccharides such as arabinogalactans from a larch tree are disclosed in US 2,073,616 and US 4,950,751.

20 US 5,096,708 shows the induction of T-helper cells by thuja polysaccharides and the antiviral effect against retroviruses *in vitro*.

A preferred preparation according to the present invention, comprises chlorogenic acid and/or a functional analog thereof and N-acetylcystein, for medical use. Surprisingly such a preparation shows a particularly well synergistic effect in medical use. Not only is NAC capable of
25 inducing interferon-gamma, but it is also a scavenger of hydrogen peroxide and may inhibit activation of NF- κ B and (rhinovirus mediated) IL-8 release. Furthermore NAC may enhance the glutathion status, which may be important for providing protection against oxygen radical related damage.
30 Preferably the weight to weight ratio of chlorogenic acid and/or a functional

analog thereof (CA-compound) to N-acetylcystein (NAC) is about 0.005-4 CA-compound/NAC, more preferably 0.02-1 CA-compound/NAC and most preferably 0.045-0.5 CA-compound/NAC.

In a preferred embodiment the preparation further comprises one or more additional ingredients, such as anti-inflammatory agents, antioxidants, trace elements, minerals, vitamins, extracts of plants and the like.

Under specific conditions, as for example can occur in patients that suffer from chronically inflamed tissues, it may be advantageous to include certain anti-inflammatory components in the composition. Preferred anti-inflammatory agents are acetylsalicylic acid, apocynin, curcumin and equivalents thereof as well as mixtures of these components. As an equivalent of acetylsalicylic acid can be considered salicylic acid or salts thereof as well as extracts of plants that are sources of these compounds, such as *Salix spp.* Functional equivalents of apocynin are considered to be related acetophenones and glycosides thereof, such as those that can be found in *Picrorhiza* species. Curcumin can be applied as pure synthetic component, as a functional analog - such as tetrahydroxy-curcumin- or as an extract from a plant that is rich in *Curcuma* species.

Effective amounts of these anti-inflammatory compounds are known in the art and are usually in the range of 5-4000 mg, and preferably 50-1000 mg per daily dose of acetylsalicylic acid, apocynin or curcumin or analogs thereof.

A preparation according to the present invention preferably comprises one or more other antioxidants, other than a CA-compound or NAC. Ascorbic acid and α -tocopherol are particularly preferred examples of suitable antioxidants in the preparation. Other suitable antioxidants are for example flavenoids, catechins, proanthocyanidins or other polyphenols.

In a preferred embodiment the preparation comprises one or more trace elements, such as manganese, copper or selenium. A trace element may be added in a solution or a crystalline form, e.g. of a medical grade trace

element oxide, -carbonate, -citrate, gluconate and the like. A trace element may also be added to the preparation in the form of a natural product, rich or enriched in trace elements, e.g. a yeast or a plant extract. Trace elements may have various functions. Several trace elements, including manganese, copper and selenium, are vital elements of various enzymes. Enzymes like superoxide dismutases (e.g. those that are copper-dependent) and glutathion peroxidase (selenium dependent) can act as antioxidants. Furthermore trace element supplements may be administered in a case of a potential deficiency of a trace element in a patient e.g. as a symptom of a disease or as the result of the administration of a particular (pharmaceutical) compound, such as NAC, of which it is known that it may lead to an increase of urinary zinc excretion.

A preferred preparation comprises an extract of one or more plants, such as plant extracts from *Echinacea*, e.g. *Echinacea purpurea*, *Astragalus membranaceus*, *Panax ginseng*, artichoke and the like. These extracts may be alcoholic and/or aqueous extracts. *Echinacea* extract is preferably obtained from the dried pressed juice of the fresh "subterranean" parts of the plant, or alternatively by an aqueous-ethanolic extract of the roots, standardized to alkylamides; *Ginseng* may be prepared according to any method and is preferably standardized to ginsenosides or polysaccharides; Artichoke may be prepared according to any method and is preferably standardized to caffeoyl acid derivatives.

The extracts may be dried, or mixed in a liquid and may provide various active compounds, such as polysaccharides which have been found capable of inducing release of interferons or have another function.

Particularly good results have been achieved with preparations comprising one or more compounds selected from the group formed by ginsenosides, beta glucans, e.g. β -1,3-D-glucan, lipoic acids and L-carnitine and analogs thereof.

A lipoic acid, preferably alfa-lipoic acid (thioctic acid) can be included as pure synthetic compound, such as a racemate of the oxidized form.

It could however also be in the form of the pure biologically active isomer in reduced form. Analogs are considered to be salts thereof as well as the lipoic acid amide. The compound is preferably administered in an amount of 1-100 mg per daily dose.

5 L-carnitine may be present as a synthetic compound or as acylated compound. The daily consumption of carnitine is typically in the range of 0.01-2 grams.

β -glucans can be isolated from plants (e.g. barley) or micro-organisms (*Saccharomyces* sp). Isolation methods are known in the art (e.g. EP 10 0 606 080 and WO 92-13896). The daily dose of β -glucans is preferably 0.2-10 grams

 A preparation may also comprise additives such as flavors, coloring agents, aroma's, preservatives and the like. A variety of examples of such additives are known from the art.

15 A preparation according to the invention can be widely used for a variety reasons and to a variety of subjects of any age and of various species including humans. The concentration of a substance present in a preparation according to the invention may vary widely based upon several factors. These factors include the species to be treated (e.g. cattle, a pet or a human), the
20 condition of the subject to be treated, the reason for administration (e.g. a particular diagnosis or prophylaxis), or the form of a preparation (e.g. a concentrated tablet, dissolved in a drink or mixed in cattle- or pet feed). In a preferred embodiment a preparation comprises one or more substances shown in Table 1, more preferably in a daily dose as indicated in Table 1. Herein
25 "daily dose" is used to describe a daily dose for a primate having a body weight 70 kg, unless stated otherwise. Methods to calculate the daily dose for other subjects will be known to the skilled professional. Once the daily dose is determined it can be calculated how much of a certain preparation needs to be administered, knowing the (approximate) fraction of active components and
30 additives in the preparation.

Table 1: Preferred daily dose (based upon a preparation for a primate) of some substances in a preparation for stimulating T-lymphocytes *in vivo*.

Substance	preferred relative concentration (daily dose in mg)
Chlorogenic acid and/or functional analogs thereof (CA-compounds)	0.5-500
N-acetylcystein	50-2000
Zinc (ionic)	1-200
Beta glucans	2-200
<i>Echinacea extract (e.g. Echinacea premium)</i>	200-2000
Ginsenosides (e.g. as extract from <i>Panax Ginseng</i>)	0.2-150
Ascorbic acid	10-1000
α -tocopherol	1-1000
Copper (ionic)	0.1-20
Selenium(ionic)	0.005-0.3
lipoic acid	1-100
L-carnitine	10-2000
<i>Astragalus membranaceus</i> extract (dry material)	200-20000

5 In a much preferred embodiment, the preparation comprises 2-300 mg/day, and a most preferably 10-200 mg/day, of one or more CA-compounds and 50-2000 mg/day N-acetylcystein, plus optionally one or more of the other compounds in an amount as can be deducted from Table 1. Most preferably N-acetylcystein is present in a daily dose of 100-1000mg.

10 Particularly preferred are also preparations comprising one or more CA-compounds, zinc and/or one or more polysaccharides in a concentration in the range shown in Table 1.

In another preferred embodiment a preparation comprises a mixture of 4-caffeoylquinic acid, 5-caffeoylquinic acid and 1,5-dicaffeoylquinic acid in a dose of 2-300 mg. A preferred distribution of CA-compounds in such a dose is 25-40 mole% 4-caffeoylquinic acid, 25-40 mole% 5-caffeoylquinic acid and 25-40 mole% 1,5-dicaffeoylquinic acid. In a more preferred preparation the distribution of CA-compounds is 30-35 mole% for each of these three compounds.

When present, substances mentioned in Table 1, are preferably present in a preparation to match the daily recommended dose as indicated in Table 1.

It is further an advantage of the invention that the CA-compounds and other components comprised by the preparation are often natural products, which have substantially no negative side effects upon administration. This makes it possible to market the preparation as an over the counter drug, which means that it can be sold without prescription of a physician. Moreover it has surprisingly been found that it is possible to process preparations according to the invention in food&drinks products, which may further facilitate the accessibility of products of the invention to the public, which more and more becomes aware of the importance of health-food products as an aid to maintain one's general health. The invention also provides in a novel food&drink product, by its capability to stimulate the immune system, and in particular T-lymphocytes.

For the manufacture of a product for stimulating T-lymphocytes *in vivo*, a preparation according to the invention may be used. The preparation may be processed by methods known from the pharmaceutical and food&drinks processing industries into a pharmaceutical, a drink or a food product.

In a preferred embodiment the preparation may be in a more or less solid form such as a capsule, a tablet, a lozenge, a powder, an agglomerate, a snack, a bar or a paste. The preparation may also be a solution, a liquid or a

semi-liquid shaped product, such as a gel, an emulsion, a suspension, a drink (such as a lemonade, a fruit juice, a dairy drink) a pudding, an ice cream, a sauce and the like.

5 A preparation may be processed in a drink or food product at the factory. A drink, comprising a daily dose may for example be packed in a 250 ml package, or another volume that is suitably consumed by a subject. In another embodiment the active components are present in a bar of typically up to 25 g, which may further comprise typically at least 60 % of (sweet) carbohydrates. In another embodiment, a preparation, e.g. a powder, a liquid,
10 a suspension and the like, may be administered to a drink or food, such as a dessert or a juice, relatively shortly before oral intake. Such a preparation may for example substantially consist of active components and may in principle be administered by anyone.

The preparation may also be a complete food product, e.g. for
15 patients on a particular (strict) diet or for cancer patients.

In a preferred method for stimulating T-lymphocytes, a preparation according to the invention is administered to a patient, in the form of a capsule, a tablet, a powder or a lozenge. In another embodiment the preparation may be administered in another form such as drops or a potion.

20 For the formulation of the dosage form, the above described preparation may suitably be combined with a pharmaceutically acceptable carrier. A much preferred dosage form is the tablet, in which the preparation may be combined with usual tablet constituents such as filler-binders, lubricants and the like.

25 The dosage in which the preparation is to be administered will of course depend on the concentration of active ingredients of the preparation and on the severity of the medical disorder or disease that is to be treated or prevented. The person skilled in the art will be able to optimize and formulate a suitable dosage scheme based on his ordinary knowledge of the field.

Preferably the preparation is orally administered, although other administration methods known in the art may also be applied, for some embodiments.

5 The packaging preferably occurs to facilitate convenience of packaging, storage, transport and/or consumption, and to ensure stability of the product, using methods known in the art.

The invention will now be further elucidated by the following, non-restrictive examples.

10

EXAMPLE 1

Tablet for stimulating T-lymphocytes *in vivo*

Main Purpose: for use in prevention and/or treatment of common cold and *influenza*

Daily Dose: 2 tablets

15

Table 2: active compounds in a tablet

Substance	Amount	Extra information
Ascorbic Acid (95 %)	125 mg	
Sodium selenate ¹ (selenium yeast 0.2 %)	85 µg	(providing 35 µg Selenium)
Zinc citrate ²	22 mg	(providing 7.5 mg Zinc)
Cupric Gluconate ³	7.5 mg	(providing 1 mg Copper)
N-acetylcysteine (99 %)	200 mg	
Dried pressed <i>Echinacea purpura</i> juice (Flachsman)	200 mg	(no significant amount of chlorogenic acid reported)
Dried extract of artichoke (globe artichoke extract 5 % chlorogenic acid)	180 mg	(providing 9 mg chlorogenic acid)
Dried extract of <i>Panax ginseng</i> (14 % ginsenosides)	50 mg	(providing 7 mg ginsenosides)
Dried (1:4) extract of <i>Astragalus membranaceus</i> (crude drug extract ratio; Nutratech)	250 mg	(no significant amount of chlorogenic acid reported)

¹ Alternatively also other form of selenium, such as sodium selenite or selenomethionine or a combination thereof may be used. Sodium may be replaced by another counter ion, such as potassium.

² Alternatively also zinc oxide (about 80% Zn), zinc carbonate (about 52% Zn), other zinc salts or a combination thereof may be used.

³ Alternatively also cupric oxide (about 80% Cu) and/or other copper salts may be used.

5 ^{1,2,3} Also yeast that is enriched with these trace elements may be used.
tablet was made by mixing and pressing as known in the art.

EXAMPLE 2

10 Powder for stimulating T-lymphocytes *in vivo*; for use in drink or dessert

Main Purpose: for use in treatment common cold

Daily Dose: powder from one sachet

Table 3: active compounds in one sachet with powder

Substance	Amount	Extra information
Ascorbic Acid	250 mg	
Sodium selenate	170 µg	(providing 70 µg Selenium)
Zinc citrate	45 mg	(providing 15 mg Zinc
Cupric Gluconate	15 mg	(providing 2 mg Copper)
N-acetylcysteine	100 mg	
β 1,3 D glucans	8 mg	
Dried pressed <i>Echinacea purpurea</i> juice	900 mg	
Chlorogenic acid	18 mg	
Dried extract of <i>Panax ginseng</i>	120 mg ¹	(providing 17 mg ginsenosides)
Maltodextrins	5 g	
Flavor	100 mg	

15 ¹ In an alternative preparation 200 mg dried extract of *Panax ginseng* was used.

EXAMPLE 3

Tablet for stimulating T-lymphocytes *in vivo*

Main Purpose: prevention and/or treatment of common cold and *influenza*

5

Table 4: active compounds in a tablet

Substance	Amount
Ascorbic Acid	60 mg
α -Tocopherol	20 mg
Sodium selenite	80 μ g
Zinc oxide	22 mg
N-acetylcysteine	200 mg
Chlorogenic acid	30 mg

Tablets were made by the same method as in Example 1.

10

EXAMPLE 4

A preparation was made according to Table 3, but Chlorogenic acid was replaced by an mixture of 20 mg 4-caffeoyl quinic acid, 20 mg 5-caffeoylquinic acid and 30 mg 1,5-dicaffeoylquinic acid.

15

EXAMPLE 5


Preparations according to examples 1-3 were made wherein the Echinacea (Flachsman) extract was replaced by a mixture of pupurea root ethanol/water extract (53 %) and *E. angustifolia* root ethanol/water extract (47%) standardized to approximately 2 % alkylamides (Mediherb).

20

Furthermore *Panax ginseng* was replaced by *Panax quinquefolium* aqueous extract containing mainly oligosaccharides and polysaccharides (CV Technologies).


Claims

1. A preparation for stimulating or enhancing an immune system comprising one or more agents that stimulate T-lymphocytes *in vivo*.
2. A preparation according to claim 1 wherein the one or more agents that stimulate T-lymphocytes *in vivo* comprise chlorogenic acid and/or one or
5 more functional analogs thereof.
3. A preparation according to claim 2, wherein said functional analog is selected from the group of chlorogenic acid, 4-caffeoylquinic acid, 5-caffeoylquinic acid and 1,5-dicaffeoylquinic acid, an isochlorogenic acid, 3,4,5-tricaffeoyl quinic acid, 1-O-caffeoylquinic acid, 1,3-O-caffeoylquinic acid),
10 1,3,4,5-O-tetracaffeoylquinic acid or 5-O-caffeoylshikimic acid.
4. A preparation according to claim 1, wherein said agent is a compound represented by formula 1,



(Formula 1)

- wherein "a" represents either a single bond or a double bond, and R₁ is only
15 present in case "a" represents a single bond, and wherein at least one of the functional groups R₁-R₄ represents a functional group represented by formula
2



(Formula 2)

and the remaining of said functional groups R1-R4 are independently chosen from the group formed by -OH and caffeic acid analogs abundant in a material of a vegetable nature.

5. A preparation according to claim 2, wherein said chlorogenic acid
5 and/or a functional analog thereof originates from one or more plants.

6. A preparation according to claim 5, wherein the extracts have been
taken from the group of *Echinacea* sp., *Panax Ginseng*, green coffee bean,
green cacao bean, hawthorn, green tea, elder tree, artichoke, guerana,
butterbur, Phoenix spp, *Butia capitata*, Dandelion, a dicotylus *Compositae* or
10 orhter dicotylus , *Arnica montana*, Birch tree or combinations thereof.

7. A preparation according to claim 1, further comprising one or more
agents capable of inducing the production of interferon-gamma.

8. A preparation according to claim 7, wherein said one or more agents
are chosen from the group formed by N-acetylcysteine, polysaccharides and
15 zinc.

9. A preparation according to claim 1, comprising one or more
arabinogalactans from *Baptisa tinctoria*, *Echinacea* species, *Larix occidentalis*,
Angelica acutiloba and/or other polysaccharides from *Echinacea* species, *Thuja*
occidentalis, *Panax ginseng*, *Flammulina velupites*, *Arnica montana*, *Plantago*
20 *spp*, *Achyrocline satureioides*, *Aconitum officinalis*, *Angelica acutiloba*,
Aristolochia officinalis, *Astralagus gummerifa*, *A. membranaceus*, *A.*
mongholicus, *Avena sativa*, *Bambusa vulgaris*, *Baptisia tinctoria*, *Bryonia*
dioica, *Calendula officinalis*, *Carthamus tinctorius*, *Chamomilla recutita*,
Echinacea angustifolia, *E. pallida*, *E. purpurea*, *Eleutherococcus senticosus*,
25 *Eupatorium cannabinum*, *Silene vulgaris*, *Triticum sativum*, *Vincetoxicum*
officinalis, *Viscum album*.

10. A preparation according to claim 1 comprising one or more additives
selected from the group of a ginsenoside, a beta glucan, an antioxidant, a trace
element, lipoic acid, L-carnitine, a mineral, a vitamin, an immuno-stimulant,
30 an anti-tumor agent and *Astragalus membranaceus* extract.

11. A preparation according to claim 10, wherein the antioxidant is chosen from the group of ascorbic acid, α -tocopherol or a combination thereof.
12. A preparation according to claim 10, wherein the trace element is chosen from the group of manganese ions, copper ions, selenium ions, selenium compounds or a combination thereof.
13. A preparation according to claim 1 comprising: 10-200 mg chlorogenic acid and or functional analogs thereof, 50-2000 mg N-acetylcystein, 200-2000 mg *Echinacea premium*, 0.2-150 mg ginsenosides, 2-200 mg beta glucans, 10-1000 mg ascorbic acid, 1-1000 mg α -tocopherol, 1-200 mg zinc, 0.1-20 mg copper, 0.005-0.3 mg selenium, 1-100 mg lipoic acid, 10-2000 mg L-carnitine, and/or *Astragalus membranaceus* extract of 200-20000 mg dry material.
14. A preparation according to claim 1 in the form of a capsule, a tablet, a lozenge, a powder, an agglomerate, a paste, a solution, a liquid, a gel, an emulsion, a suspension, a bar, a drink, a pudding, an ice cream or a sauce.
15. A preparation comprising chlorogenic acid and/or a functional analog thereof further comprising N-acetylcystein, for medical use.
16. A preparation according to claim 1 or 15 in a pharmaceutical, drink or food product.
17. A preparation according to claim 1 for use in treatment and/or prophylaxis of cancer, infection by a parasite, a toxin, a virus, and/or a bacterium.
18. A preparation according to claim 17 for use in treatment and/or prophylaxis of an infection by an infectant selected from the group of Poxviridae, Herpesviridae, Adenoviridae, Papavoviridae, Hepadnaviridae, Parvoviridae, Reoviridae, Picornaviridae, Togaviridae, Flaviviridae, Coronaviridae, Rhabdoviridae, Paramyxoviridae, Orthomyxoviridae, Filoviridae, Bunyaviridae, Arenaviridae, Caliciviridae, Retroviridae, Papilloma, influenza, HIV, HTLV, Corona, Epstein Barr, pneumococcus, staphylococcus aureus and/or combinations thereof.

19. A method for stimulating T-lymphocytes by administration of a preparation according to any of the claims 1-18.
20. A method according to claim 19, wherein the method is part of a prophylactic or treatment protocol for cancer.
- 5 21. The use of a preparation according to claim 1 for the manufacture of a product for stimulating T-lymphocytes.
22. A vaccine comprising chlorogenic acid or a functional analog thereof as adjuvant.
23. The use of chlorogenic acid or a functional analog thereof as an
10 adjuvant in a vaccine.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 June 2002 (20.06.2002)

PCT

(10) International Publication Number
WO 02/047703 A3

- (51) International Patent Classification⁷: A61K 35/78, A61P 37/04, A61K 31/215 (74) Agent: PRINS, A., W.; c/o Vereenigde, Nieuwe Parklaan 97, NL-2587 BN The Hague (NL).
- (21) International Application Number: PCT/NL01/00896 (81) Designated States (*national*): AE, AG, AL, AM, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU (inventor's certificate), CZ (utility model), DE (utility model), DK (utility model), DM, DZ, EC, EE (utility model), ES, FI (utility model), GB, GD, GE, GH (utility certificate), GM, HR (consensual patent), HU, ID, IL, IN, IS, JP, KE, KG, KP (inventor's certificate), KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK (utility model), SL, TJ, TM, TN, TR, TT (utility certificate), TZ, UA, UG (utility certificate), US, UZ, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: 10 December 2001 (10.12.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 09/734,389 11 December 2000 (11.12.2000) US
- (61) Related by addition to earlier applications or grants:
CU Not furnished (ICA)
Filed on Not furnished
KP Not furnished (ICA)
Filed on Not furnished
- (71) Applicant (*for all designated States except US*): NUTRICIA N.V. [NL/NL]; Eerste Stationsstraat 186, NL-2712 HM Zoetermeer (NL).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): GRAUS, Yvo, Maria, Franciscus [NL/NL]; Pienemanstraat 112, NL-6717 WG Ede (NL). SMIT, Hobbe, Friso [NL/NL]; Texel 7, NL-3524 AS Utrecht (NL). OSTERHAUS, Albertus, Dominicus, Marcellinus, Erasmus [NL/NL]; Dr. Breveestraat 16, NL-3981 CH Bunnik (NL). HAGEMAN, Robert, Johan, Joseph [NL/NL]; Weidezoo 52, NL-2742 EV Waddinxveen (NL).
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 12 September 2002
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: IMMUNE SYSTEM STIMULATION

(57) Abstract: The present invention relates to a preparation for stimulating or enhancing an immune system comprising one or more agents that stimulate T-lymphocytes *vivo*. Such a preparation can be used in the prophylaxis and/or treatment of a medical condition. The invention further relates to a preparation for use in a pharmaceutical or food product and to a preparation for medical use.

WO 02/047703 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/NL 01/00896

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61K35/78 A61P37/04 A61K31/215

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6 083 921 A (XU KAI JIAN) 4 July 2000 (2000-07-04) column 1, line 54-56; claims 1,3 ---	1-23
X	EP 1 008 344 A (INST OF RADIATION MEDICINE ACA) 14 June 2000 (2000-06-14) page 12, line 22; claims 1,7; table 7 ---	1-23
X	WO 98 11778 A (SQUIRES MERYL) 26 March 1998 (1998-03-26) claims 1-6 ---	1-23
X	EP 0 317 453 A (IPHYM SA SOCIETE ANONYME) 24 May 1989 (1989-05-24) claims 1,3,4 -----	1-23



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

26 June 2002

Date of mailing of the international search report

03/07/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Beyss, E

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/NL 01/00896

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 6083921	A	04-07-2000	AU 2107599 A CA 2317453 A1 EP 1047439 A1 WO 9934812 A1	26-07-1999 15-07-1999 02-11-2000 15-07-1999
EP 1008344	A	14-06-2000	CN 1175411 A AU 4008597 A BR 9711647 A EP 1008344 A2 JP 2000517323 T US 6331565 B1 WO 9809599 A2	11-03-1998 26-03-1998 06-06-2000 14-06-2000 26-12-2000 18-12-2001 12-03-1998
WO 9811778	A	26-03-1998	US 6355684 B1 AU 716247 B2 AU 3715397 A BG 102984 A BR 9711086 A CA 2253736 A1 CZ 9803594 A3 EE 9800382 A EP 0918458 A1 JP 2001505546 T NO 985200 A NZ 332650 A PL 330314 A1 SK 153398 A3 TR 9802251 T2 WO 9811778 A1 US 6350784 B1	12-03-2002 24-02-2000 14-04-1998 30-09-1999 11-01-2000 26-03-1998 16-06-1999 15-04-1999 02-06-1999 24-04-2001 08-01-1999 29-11-1999 10-05-1999 08-10-1999 21-06-2001 26-03-1998 26-02-2002
EP 0317453	A	24-05-1989	FR 2623398 A1 AT 85222 T DE 3878169 D1 DE 3878169 T2 EP 0317453 A1 ES 2053793 T3 GR 3007353 T3	26-05-1989 15-02-1993 18-03-1993 05-08-1993 24-05-1989 01-08-1994 30-07-1993

THIS PAGE BLANK (USPTO)

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
20 June 2002 (20.06.2002)

PCT

(10) International Publication Number
WO 2002/047703 A3

(51) International Patent Classification⁷: **A61K 35/78**,
A61P 37/04, A61K 31/215

(21) International Application Number:
PCT/NL2001/000896

(22) International Filing Date:
10 December 2001 (10.12.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/734,389 11 December 2000 (11.12.2000) US

(61) Related by addition to earlier applications or grants:
CU Not furnished (ICA)
Filed on Not furnished
KP Not furnished (ICA)
Filed on Not furnished

(71) Applicant (for all designated States except US): NUTRI-
CIA N.V. [NL/NL]; Eerste Stationsstraat 186, NL-2712
HM Zoetermeer (NL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): GRAUS, Yvo,
Maria, Franciscus [NL/NL]; Pienemanstraat 112,
NL-6717 WG Ede (NL). SMIT, Hobbe, Friso [NL/NL];
Texel 7, NL-3524 AS Utrecht (NL). OSTERHAUS,
Albertus, Dominicus, Marcellinus, Erasmus [NL/NL];
Dr. Brevestraat 16, NL-3981 CH Bunnik (NL). HAGE-
MAN, Robert, Johan, Joseph [NL/NL]; Weidezoo 52,
NL-2742 EV Waddinxveen (NL).

(74) Agent: PRINS, A., W.; c/o Vereenigde, Nieuwe Parklaan
97, NL-2587 BN The Hague (NL).

(81) Designated States (*national*): AE, AG, AL, AM, AT (util-
ity model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN, CO, CR, CU (inventor's certificate), CZ (utility
model), CZ, DE (utility model), DE, DK (utility model),
DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility
model), FI, GB, GD, GE, GH (utility certificate), GM, HR
(consensual patent), HU, ID, IL, IN, IS, JP, KE, KG, KP
(inventor's certificate), KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM,
PH, PL, PT, RO, RU, SD, SE, SG, SI, SK (utility model),
SK, SL, TJ, TM, TN, TR, TT (utility certificate), TZ, UA,
UG (utility certificate), US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
12 September 2002

(48) Date of publication of this corrected version:
13 May 2004

(15) Information about Correction:
see PCT Gazette No. 20/2004 of 13 May 2004, Section II

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: IMMUNE SYSTEM STIMULATION

(57) Abstract: The present invention relates to a preparation for stimulating or enhancing an immune system comprising one or more agents that stimulate T-lymphocytes *vivo*. Such a preparation can be used in the prophylaxis and/or treatment of a medical condition. The invention further relates to a preparation for use in a pharmaceutical or food product and to a preparation for medical use.

WO 2002/047703 A3

THIS PAGE BLANK (USPTO)